Enhanced acetate uptake and metabolism in endothelial cells promote tumour angiogenesis and immunosuppression by increasing histone acetylation.
Blocking a metabolic pathway in tumor blood vessels enhances immunotherapy effectiveness against liver cancer in laboratory models.
Hepatic acetate accumulation drives MCT1/ACSS2 upregulation in tumor endothelial cells, increasing H3K27ac-mediated pro-angiogenic and immunosuppressive transcription; ACSS2 inhibition synergizes with anti-PD-1 to suppress HCC progression and enhance CD8+ T-cell immunity. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- experimental (mechanistic, multiple mouse models + human samples)
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- Gut
Why it surfaced
Published in Gut (top GI/hepatology journal); identifies a completely novel metabolic immune suppression pathway in tumor endothelial cells; strong preclinical mechanistic evidence with therapeutic synergy data; highly actionable for HCC immunotherapy combination strategy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.